|
1
|
Jung KW, Park S, Kong HJ, Won YJ, Lee JY,
Seo HG and Lee JS: Cancer statistics in Korea: incidence,
mortality, survival, and prevalence in 2009. Cancer Res Treat.
44:11–24. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tsai HL, Chu KS, Huang YH, Su YC, Wu JY,
Kuo CH, Chen CW and Wang JY: Predictive factors of early relapse in
UICC stage I-III colorectal cancer patients after curative
resection. J Surg Oncol. 100:736–743. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee SJ, Choi SY, Kim WJ, Ji M, Lee TG, Son
BR, Yoon SM, Sung R, Lee EJ, Youn SJ and Park SM: Combined aberrant
expression of E-cadherin and S100A4, but not β-catenin is
associated with disease-free survival and overall survival in
colorectal cancer patients. Diagn Pathol. 8:992013. View Article : Google Scholar
|
|
4
|
He X, Chen Z, Jia M and Zhao X:
Downregulated E-cadherin expression indicates worse prognosis in
Asian patients with colorectal cancer: evidence from meta-analysis.
PLoS One. 8:e708582013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Findlay VJ, Wang C, Watson DK and Camp ER:
Epithelial-to-mesenchymal transition and the cancer stem cell
phenotype: insights from cancer biology with therapeutic
implications for colorectal cancer. Cancer Gene Ther. 21:181–187.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mariadason JM: HDACs and HDAC inhibitors
in colon cancer. Epigenetics. 3:28–37. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen X, Wong P, Radany E and Wong JY: HDAC
inhibitor, valproic acid, induces p53-dependent radiosensitization
of colon cancer cells. Cancer Biother Radiopharm. 24:689–699. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Meng J, Zhang HH, Zhou CX, Li C, Zhang F
and Mei QB: The histone deacetylase inhibitor trichostatin A
induces cell cycle arrest and apoptosis in colorectal cancer cells
via p53-dependent and -independent pathways. Oncol Rep. 28:384–388.
2012.PubMed/NCBI
|
|
9
|
Hsu YF, Sheu JR, Lin CH, Yang DS, Hsiao G,
Ou G, Chiu PT, Huang YH, Kuo WH and Hsu MJ: Trichostatin A and
sirtinol suppressed survivin expression through AMPK and p38MAPK in
HT29 colon cancer cells. Biochim Biophys Acta. 1820:104–115. 2012.
View Article : Google Scholar
|
|
10
|
Xiong H, Du W, Zhang YJ, Hong J, Su WY,
Tang JT, Wang YC, Lu R and Fang JY: Trichostatin A, a histone
deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing
the promoter-associated histone acetylation of SOCS1 and SOCS3 in
human colorectal cancer cells. Mol Carcinog. 51:174–184. 2012.
View Article : Google Scholar
|
|
11
|
Habold C, Poehlmann A, Bajbouj K, Hartig
R, Korkmaz KS, Roessner A and Schneider-Stock R: Trichostatin A
causes p53 to switch oxidative-damaged colorectal cancer cells from
cell cycle arrest into apoptosis. J Cell Mol Med. 12:607–621. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marchion D and Munster P: Development of
histone deacetylase inhibitors for cancer treatment. Expert Rev
Anticancer Ther. 7:583–598. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mologni L, Cleris L, Magistroni V, Piazza
R, Boschelli F, Formelli F and Gambacorti-Passerini C: Valproic
acid enhances bosutinib cytotoxicity in colon cancer cells. Int J
Cancer. 124:1990–1996. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
DI Fazio P, Montalbano R, Quint K, Alinger
B, Kemmerling R, Kiesslich T, Ocker M and Neureiter D: The
pan-deacetylase inhibitor panobinostat modulates the expression of
epithelial-mesenchymal transition markers in hepatocellular
carcinoma models. Oncol Lett. 5:127–134. 2013.
|
|
15
|
Shah P, Gau Y and Sabnis G: Histone
deacetylase inhibitor entinostat reverses epithelial to mesenchymal
transition of breast cancer cells by reversing the repression of
E-cadherin. Breast Cancer Res Treat. 143:99–111. 2014. View Article : Google Scholar
|
|
16
|
Srivastava RK, Kurzrock R and Shankar S:
MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits
angiogenesis and metastasis, and reverses epithelial-mesenchymal
transition in vivo. Mol Cancer Ther. 9:3254–3266. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Taylor MD, Liu Y, Nagji AS, Theodosakis N
and Jones DR: Combined proteasome and histone deacetylase
inhibition attenuates epithelial-mesenchymal transition through
E-cadherin in esophageal cancer cells. J Thorac Cardiovasc Surg.
139:1224–1232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Meng F, Sun G, Zhong M, Yu Y and Brewer
MA: Anticancer efficacy of cisplatin and trichostatin A or
5-aza-2′-deoxycytidine on ovarian cancer. Br J Cancer. 108:579–586.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kaimori A, Potter JJ, Choti M, Ding Z,
Mezey E and Koteish AA: Histone deacetylase inhibition suppresses
the transforming growth factor beta1-induced
epithelial-to-mesenchymal transition in hepatocytes. Hepatology.
52:1033–1045. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xiao W, Chen X, Liu X, Luo L, Ye S and Liu
Y: Trichostatin A, a histone deacetylase inhibitor, suppresses
proliferation and epithelial-mesenchymal transition in retinal
pigment epithelium cells. J Cell Mol Med. 18:646–655. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen X, Xiao W, Chen W, Luo L, Ye S and
Liu Y: The epigenetic modifier trichostatin A, a histone
deacetylase inhibitor, suppresses proliferation and
epithelial-mesenchymal transition of lens epithelial cells. Cell
Death Dis. 4:e8842013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshikawa M, Hishikawa K, Marumo T and
Fujita T: Inhibition of histone deacetylase activity suppresses
epithelial-to-mesenchymal transition induced by TGF-beta1 in human
renal epithelial cells. J Am Soc Nephrol. 18:58–65. 2007.
View Article : Google Scholar
|
|
23
|
Kong D, Ahmad A, Bao B, Li Y, Banerjee S
and Sarkar FH: Histone deacetylase inhibitors induce
epithelial-to-mesenchymal tranasition in prostate cancer cells.
PLoS One. 7:e450452012. View Article : Google Scholar
|
|
24
|
Giudice FS, Pinto DS Jr, Nör JE, Squarize
CH and Castilho RM: Inhibition of histone deacetylase impacts
cancer stem cells and induces epithelial-mesenchyme transition of
head and neck cancer. PLoS One. 8:e586722013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang GM, Wang HS, Zhang F, Zhang KS, Liu
ZC, Fang R, Wang H, Cai SH and Du J: Histone deacetylase inhibitor
induction of epithelial-mesenchymal transitions via up-regulation
of Snail facilitates cancer progression. Biochim Biophys Acta.
1833:663–671. 2013. View Article : Google Scholar
|
|
26
|
Pino MS, Kikuchi H, Zeng M, Herraiz MT,
Sperduti I, Berger D, Park DY, Iafrate AJ, Zukerberg LR and Chung
DC: Epithelial to mesenchymal transition is impaired in colon
cancer cells with microsatellite instability. Gastroenterology.
138:1406–1417. 2010. View Article : Google Scholar :
|
|
27
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu Y, Zhang X, Salmon M and Zehner ZE: The
zinc finger repressor, ZBP-89, recruits histone deacetylase 1 to
repress vimentin gene expression. Genes Cells. 12:905–918. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Uchida H, Maruyama T, Nishikawa-Uchida S,
Oda H, Miyazaki K, Yamasaki A and Yoshimura Y: Studies using an in
vitro model show evidence of involvement of epithelial-mesenchymal
transition of human endometrial epithelial cells in human embryo
implantation. J Biol Chem. 287:4441–4450. 2012. View Article : Google Scholar :
|
|
30
|
Xu WS, Parmigiani RB and Marks PA: Histone
deacetylase inhibitors: molecular mechanisms of action. Oncogene.
26:5541–5552. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gujral TS and MacBeath G: A system-wide
investigation of the dynamics of Wnt signaling reveals novel phases
of transcriptional regulation. PLoS One. 5:e100242010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Elzagheid A, Algars A, Bendardaf R, Lamlum
H, Ristamaki R, Collan Y, Syrjanen K and Pyrhonen S: E-cadherin
expression pattern in primary colorectal carcinomas and their
metastases reflects disease outcome. World J Gastroenterol.
12:4304–4309. 2006.PubMed/NCBI
|
|
33
|
Céspedes MV, Larriba MJ, Pavón MA, Alamo
P, Casanova I, Parreño M, Feliu A, Sancho FJ, Muñoz A and Mangues
R: Site-dependent E-cadherin cleavage and nuclear translocation in
metastatic colorectal cancer model. Am J Pathol. 177:2067–2079.
2010. View Article : Google Scholar
|
|
34
|
Han AC, Soler AP, Tang CK, Knudsen KA and
Salazar H: Nuclear localization of E-cadherin expression in Merkel
cell carcinoma. Arch Pathol Lab Med. 124:1147–1151. 2000.PubMed/NCBI
|
|
35
|
Moon KC, Cho SY, Lee HS, Jeon YK, Chung
JH, Jung KC and Chung DH: Distinct expression patterns of
E-cadherin and beta-catenin in signet ring cell carcinoma
components of primary pulmonary adenocarcinoma. Arch Pathol Lab
Med. 130:1320–1325. 2006.PubMed/NCBI
|
|
36
|
Gervais ML, Henry PC, Saravanan A, Burry
TN, Gallie BL, Jewett MA, Hill RP, Evans AJ and Ohh M: Nuclear
E-cadherin and VHL immunoreactivity are prognostic indicators of
clear-cell renal cell carcinoma. Lab Invest. 87:1252–1264. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Salahshor S, Naidoo R, Serra S, Shih W,
Tsao MS, Chetty R and Woodgett JR: Frequent accumulation of nuclear
E-cadherin and alterations in the Wnt signaling pathway in
esophageal squamous cell carcinomas. Mod Pathol. 21:271–281. 2008.
View Article : Google Scholar
|
|
38
|
Serra S, Salahshor S, Fagih M, Niakosari
F, Radhi JM and Chetty R: Nuclear expression of E-cadherin in solid
pseudopapillary tumors of the pancreas. JOP. 8:296–303.
2007.PubMed/NCBI
|
|
39
|
Ordonez NG: Value of E-cadherin and
N-cadherin immunostaining in the diagnosis of mesothelioma. Hum
Pathol. 34:749–755. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Robertson FM, Woodward WA, Pickei R, Ye Z,
Bornmann W, Pal A, Peng Z, Hall CS and Cristofanilli M:
Suberoylanilide hydroxamic acid blocks self-renewal and homotypic
aggregation of inflammatory breast cancer spheroids. Cancer.
116:2760–2767. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lei W, Zhang K, Pan X, Hu Y, Wang D, Yuan
X, Shu G and Song J: Histone deacetylase 1 is required for
transforming growth factor-beta1-induced epithelial-mesenchymal
transition. Int J Biochem Cell Biol. 42:1489–1497. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Manoguerra AS, Erdman AR, Woolf AD, Chyka
PA, Caravati EM, Scharman EJ, Booze LL, Christianson G, Nelson LS,
Cobaugh DJ and Troutman WG: Valproic acid poisoning: an
evidence-based consensus guideline for out-of-hospital management.
Clin Toxicol (Phila). 46:661–676. 2008. View Article : Google Scholar
|
|
43
|
Insinga A, Monestiroli S, Ronzoni S,
Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S and
Pelicci PG: Inhibitors of histone deacetylases induce
tumor-selective apoptosis through activation of the death receptor
pathway. Nat Med. 11:71–76. 2005. View
Article : Google Scholar
|
